Periostin in Angiogenesis and Inflammation in CRC—A Preliminary Observational Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Preparation of Samples for the Evaluation of Periostin, VEGF-A, TNFα, IFN-γ, IL-1β and IL-17
2.2. Evaluation of Periostin, VEGF-A, TNFα, IFN-γ, IL-1β and IL-17
2.3. Immunostaining
2.4. Histological Evaluation
2.5. Statistical Analysis
3. Results
3.1. Results from Tissue Homogenates
3.2. Association with Histologic Features
4. Discussion
4.1. The Role of Periostin in Tumorigenesis
4.2. Levels of Periostin and Its Correlation with MVD and Budding
4.3. Correlations between Levels of Periostin and Selected Cytokines: IFN-γ, IL-1β, TNFα and IL-17
4.4. Lack of Correlation between Investigated Molecules and Clinical Features such as TNM Scale, Stage and Grading
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Keum, N.; Giovannucci, E. Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 713–732. [Google Scholar] [CrossRef] [PubMed]
- Al-Zalabani, A. Preventability of Colorectal Cancer in Saudi Arabia: Fraction of Cases Attributable to Modifiable Risk Factors in 2015–2040. Int. J. Environ. Res. Public Health 2020, 17, 320. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Johnson, C.M.; Wei, C.; Ensor, J.E.; Smolenski, D.J.; Amos, C.I.; Levin, B.; Berry, D.A. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control 2013, 24, 1207–1222. [Google Scholar] [CrossRef] [PubMed]
- Villanueva, C.M.; Espinosa, A.; Gracia-Lavedan, E.; Vlaanderen, J.; Vermeulen, R.; Molina, A.J.; Amiano, P.; Gómez-Acebo, I.; Castaño-Vinyals, G.; Vineis, P.; et al. Exposure to widespread drinking water chemicals, blood inflammation markers, and colorectal cancer. Environ. Int. 2021, 157, 106873. [Google Scholar] [CrossRef]
- Yaghoubi, N.; Soltani, A.; Ghazvini, K.; Hassanian, S.M.; Hashemy, S.I. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomed. Pharmacother. 2019, 110, 312–318. [Google Scholar] [CrossRef]
- Gillan, L.; Matei, D.; Fishman, D.A.; Gerbin, C.S.; Karlan, B.Y.; Chang, D.D. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 2002, 62, 5358–5364. [Google Scholar] [PubMed]
- Moniuszko, T.; Wincewicz, A.; Koda, M.; Domysławska, I.; Sulkowski, S. Role of periostin in esophageal, gastric and colon cancer. Oncol. Lett. 2016, 12, 783–787. [Google Scholar] [CrossRef] [Green Version]
- Kusunose, N.; Akamine, T.; Kobayashi, Y.; Yoshida, S.; Kimoto, K.; Yasukochi, S.; Matsunaga, N.; Koyanagi, S.; Ohdo, S.; Kubota, T. Contribution of the clock gene DEC2 to VEGF mRNA upregulation by modulation of HIF1α protein levels in hypoxic MIO-M1 cells, a human cell line of retinal glial (Müller) cells. Jpn. J. Ophthalmol. 2018, 62, 677–685. [Google Scholar] [CrossRef] [PubMed]
- Deng, X.; Ao, S.; Hou, J.; Li, Z.; Lei, Y.; Lyu, G. Prognostic significance of periostin in colorectal cancer. Chin. J. Cancer Res. 2019, 31, 547–556. [Google Scholar] [CrossRef]
- Ouyang, G.; Liu, M.; Ruan, K.; Song, G.; Mao, Y.; Bao, S. Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. Cancer Lett. 2009, 281, 213–219. [Google Scholar] [CrossRef]
- Wu, G.; Wang, X.; Zhang, X. Clinical implications of periostin in the liver metastasis of colorectal cancer. Cancer Biother. Radiopharm. 2013, 28, 298–302. [Google Scholar] [CrossRef]
- Ben, Q.-W.; Zhao, Z.; Ge, S.-F.; Zhou, J.; Yuan, F.; Yuan, Y.-Z. Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. Int. J. Oncol. 2009, 34, 821–828. [Google Scholar] [CrossRef] [Green Version]
- Janakiram, N.B.; Rao, C.V. The role of inflammation in colon cancer. Adv. Exp. Med. Biol. 2014, 816, 25–52. [Google Scholar] [CrossRef]
- Gallo, G.; Vescio, G.; de Paola, G.; Sammarco, G. Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer. J. Clin. Med. 2021, 10, 2295. [Google Scholar] [CrossRef]
- Sueyama, T.; Kajiwara, Y.; Mochizuki, S.; Shimazaki, H.; Shinto, E.; Hase, K.; Ueno, H. Periostin as a key molecule defining desmoplastic environment in colorectal cancer. Virchows Arch. 2021, 478, 865–874. [Google Scholar] [CrossRef] [PubMed]
- Klampfer, L. Cytokines, inflammation and colon cancer. Curr. Cancer Drug Targets 2011, 11, 451–464. [Google Scholar] [CrossRef] [PubMed]
- Shimoyama, Y.; Tamai, K.; Shibuya, R.; Nakamura, M.; Mochizuki, M.; Yamaguchi, K.; Kakuta, Y.; Kinouchi, Y.; Sato, I.; Kudo, A.; et al. Periostin attenuates tumor growth by inducing apoptosis in colitis-related colorectal cancer. Oncotarget 2018, 9, 20008–20017. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elliott, C.G.; Forbes, T.L.; Leask, A.; Hamilton, D.W. Inflammatory microenvironment and tumor necrosis factor alpha as modulators of periostin and CCN2 expression in human non-healing skin wounds and dermal fibroblasts. Matrix Biol. 2015, 43, 71–84. [Google Scholar] [CrossRef] [PubMed]
- Peng, Y.-Q.; Cao, M.-J.; Yoshida, S.; Zhang, L.-S.; Zeng, H.-L.; Zou, J.-L.; Kobayashi, Y.; Nakama, T.; Shi, J.-M.; Jia, S.-B.; et al. Attenuation of periostin in retinal Müller glia by TNF-α and IFN-γ. Int. J. Ophthalmol. 2019, 12, 212–218. [Google Scholar] [CrossRef]
- Amara, S.; Lopez, K.; Banan, B.; Brown, S.-K.; Whalen, M.; Myles, E.; Ivy, M.T.; Johnson, T.; Schey, K.L.; Tiriveedhi, V. Synergistic effect of pro-inflammatory TNFα and IL-17 in periostin mediated collagen deposition: Potential role in liver fibrosis. Mol. Immunol. 2015, 64, 26–35. [Google Scholar] [CrossRef] [Green Version]
- Ghajar, C.M.; Peinado, H.; Mori, H.; Matei, I.R.; Evason, K.J.; Brazier, H.; Almeida, D.; Koller, A.; Hajjar, K.A.; Stainier, D.Y.R.; et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 2013, 15, 807–817. [Google Scholar] [CrossRef]
- Bernardes, S.S.; Pinto, M.C.X.; Amorim, J.H.; de Carvalho Azevedo, V.A.; Resende, R.R.; Mintz, A.; Birbrair, A. Glioma Pericytes Promote Angiogenesis by Producing Periostin. Cell. Mol. Neurobiol. 2020, 1–8. [Google Scholar] [CrossRef]
- Koh, S.-J.; Choi, Y.; Kim, B.G.; Lee, K.L.; Kim, D.W.; Kim, J.H.; Kim, J.W.; Kim, J.S. Matricellular Protein Periostin Mediates Intestinal Inflammation through the Activation of Nuclear Factor κB Signaling. PLoS ONE 2016, 11, e0149652. [Google Scholar] [CrossRef]
- Liu, Y.; Huang, Z.; Cui, D.; Ouyang, G. The Multiaspect Functions of Periostin in Tumor Progression. Adv. Exp. Med. Biol. 2019, 1132, 125–136. [Google Scholar] [CrossRef]
- Liu, Y.; Li, F.; Gao, F.; Xing, L.; Qin, P.; Liang, X.; Zhang, J.; Qiao, X.; Lin, L.; Zhao, Q.; et al. Periostin promotes tumor angiogenesis in pancreatic cancer via Erk/VEGF signaling. Oncotarget 2016, 7, 40148–40159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- de Smedt, L.; Palmans, S.; Sagaert, X. Tumour budding in colorectal cancer: What do we know and what can we do? Virchows Arch. 2016, 468, 397–408. [Google Scholar] [CrossRef] [PubMed]
- Lugli, A.; Zlobec, I.; Berger, M.D.; Kirsch, R.; Nagtegaal, I.D. Tumour budding in solid cancers. Nat. Rev. Clin. Oncol. 2021, 18, 101–115. [Google Scholar] [CrossRef]
- Hatzikirou, H.; Basanta, D.; Simon, M.; Schaller, K.; Deutsch, A. ’Go or grow’: The key to the emergence of invasion in tumour progression? Math. Med. Biol. 2012, 29, 49–65. [Google Scholar] [CrossRef] [PubMed]
- Dawson, H.; Koelzer, V.H.; Karamitopoulou, E.; Economou, M.; Hammer, C.; Muller, D.-E.; Lugli, A.; Zlobec, I. The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology 2014, 64, 577–584. [Google Scholar] [CrossRef]
- Liu, A.Y.; Zheng, H.; Ouyang, G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol. 2014, 37, 150–156. [Google Scholar] [CrossRef]
- Esfahani, K.; Roudaia, L.; Buhlaiga, N.; Del Rincon, S.V.; Papneja, N.; Miller, W.H., Jr. A review of cancer immunotherapy: From the past, to the present, to the future. Curr. Oncol. 2020, 27, S87–S97. [Google Scholar] [CrossRef] [PubMed]
- Kosmidis, C.; Sapalidis, K.; Koletsa, T.; Kosmidou, M.; Efthimiadis, C.; Anthimidis, G.; Varsamis, N.; Michalopoulos, N.; Koulouris, C.; Atmatzidis, S.; et al. Interferon-γ and Colorectal Cancer: An up-to date. J. Cancer 2018, 9, 232–238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, B.; Wu, K.; Wang, X.; Zhang, J.; Wang, L.; Jiang, Y.; Zhu, X.; Chen, W.; Yan, M. Periostin secreted by cancer-associated fibroblasts promotes cancer stemness in head and neck cancer by activating protein tyrosine kinase 7. Cell Death Dis. 2018, 9, 1082. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- González-González, L.; Alonso, J. Periostin: A Matricellular Protein With Multiple Functions in Cancer Development and Progression. Front. Oncol. 2018, 8, 225. [Google Scholar] [CrossRef]
- Yang, T.; Deng, Z.; Pan, Z.; Qian, Y.; Yao, W.; Wang, J. Prognostic value of periostin in multiple solid cancers: A systematic review with meta-analysis. J. Cell. Physiol. 2020, 235, 2800–2808. [Google Scholar] [CrossRef] [PubMed]
- Bao, S.; Ouyang, G.; Bai, X.; Huang, Z.; Ma, C.; Liu, M.; Shao, R.; Anderson, R.M.; Rich, J.N.; Wang, X.-F. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004, 5, 329–339. [Google Scholar] [CrossRef]
- Li, Z.; Zhang, X.; Yang, Y.; Yang, S.; Dong, Z.; Du, L.; Wang, L.; Wang, C. Periostin expression and its prognostic value for colorectal cancer. Int. J. Mol. Sci. 2015, 16, 12108–12118. [Google Scholar] [CrossRef]
- Oh, H.J.; Bae, J.M.; Wen, X.-Y.; Cho, N.-Y.; Kim, J.H.; Kang, G.H. Overexpression of POSTN in Tumor Stroma Is a Poor Prognostic Indicator of Colorectal Cancer. J. Pathol. Transl. Med. 2017, 51, 306–313. [Google Scholar] [CrossRef] [Green Version]
- Ma, Y.; He, L.; Zhao, X.; Li, W.; Lv, X.; Zhang, X.; Peng, J.; Yang, L.; Xu, Q.; Wang, H. Protease activated receptor 2 signaling promotes self-renewal and metastasis in colorectal cancer through β-catenin and periostin. Cancer Lett. 2021, 521, 130–141. [Google Scholar] [CrossRef]
- Huizer, K.; Zhu, C.; Chirifi, I.; Krist, B.; Zorgman, D.; van der Weiden, M.; van den Bosch, T.P.P.; Dumas, J.; Cheng, C.; Kros, J.M.; et al. Periostin Is Expressed by Pericytes and Is Crucial for Angiogenesis in Glioma. J. Neuropathol. Exp. Neurol. 2020, 79, 863–872. [Google Scholar] [CrossRef]
- Righi, A.; Sarotto, I.; Casorzo, L.; Cavalchini, S.; Frangipane, E.; Risio, M. Tumour budding is associated with hypoxia at the advancing front of colorectal cancer. Histopathology 2015, 66, 982–990. [Google Scholar] [CrossRef]
- Qiu, F.; Shi, C.-H.; Zheng, J.; Liu, Y.-B. Periostin mediates the increased pro-angiogenic activity of gastric cancer cells under hypoxic conditions. J. Biochem. Mol. Toxicol. 2013, 27, 364–369. [Google Scholar] [CrossRef] [PubMed]
- Tung, K.-H.; Lin, C.-W.; Kuo, C.-C.; Li, L.-T.; Kuo, Y.-H.; Lin, C.-W.; Wu, H.-C. CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling. Cancer Lett. 2013, 331, 58–67. [Google Scholar] [CrossRef] [PubMed]
- Yang, P.; Yu, P.B. Periostin: A Novel Integrator of Hypoxic Signaling in Pulmonary Hypertension. Circ. Res. 2020, 127, 1153–1155. [Google Scholar] [CrossRef] [PubMed]
- Mirza, R.E.; Fang, M.M.; Novak, M.L.; Urao, N.; Sui, A.; Ennis, W.J.; Koh, T.J. Macrophage PPARγ and impaired wound healing in type 2 diabetes. J. Pathol. 2015, 236, 433–444. [Google Scholar] [CrossRef] [PubMed]
- Servais, C.; Erez, N. From sentinel cells to inflammatory culprits: Cancer-associated fibroblasts in tumour-related inflammation. J. Pathol. 2013, 229, 198–207. [Google Scholar] [CrossRef]
- Raz, Y.; Erez, N. An inflammatory vicious cycle: Fibroblasts and immune cell recruitment in cancer. Exp. Cell Res. 2013, 319, 1596–1603. [Google Scholar] [CrossRef]
- Kumar, P.; Smith, T.; Raeman, R.; Chopyk, D.M.; Brink, H.; Liu, Y.; Sulchek, T.; Anania, F.A. Periostin promotes liver fibrogenesis by activating lysyl oxidase in hepatic stellate cells. J. Biol. Chem. 2018, 293, 12781–12792. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Castro, F.; Cardoso, A.P.; Gonçalves, R.M.; Serre, K.; Oliveira, M.J. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Front. Immunol. 2018, 9, 847. [Google Scholar] [CrossRef] [Green Version]
- Dinarello, C.A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev. 2018, 281, 8–27. [Google Scholar] [CrossRef]
- Corliss, B.A.; Azimi, M.S.; Munson, J.M.; Peirce, S.M.; Murfee, W.L. Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis. Microcirculation 2016, 23, 95–121. [Google Scholar] [CrossRef] [PubMed]
- Hayashi, N.; Yoshimoto, T.; Izuhara, K.; Matsui, K.; Tanaka, T.; Nakanishi, K. T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN-gamma and IL-13 production. Proc. Natl. Acad. Sci. USA 2007, 104, 14765–14770. [Google Scholar] [CrossRef] [Green Version]
- Hus, I.; Maciag, E.; Roliński, J. The role of Th17 cells in anti-cancer immunity. Postepy Hig. Med. Dosw. (Online) 2010, 64, 244–250. [Google Scholar] [PubMed]
- Chen, Y.; Tan, W.; Wang, C. Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial-mesenchymal transition. OncoTargets Ther. 2018, 11, 3817–3826. [Google Scholar] [CrossRef] [Green Version]
- Vilcek, J.; Palombella, V.J.; Henriksen-DeStefano, D.; Swenson, C.; Feinman, R.; Hirai, M.; Tsujimoto, M. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J. Exp. Med. 1986, 163, 632–643. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, D.; Zhou, W.; Wang, Z.; Wang, Y.; Liu, M.; Zhang, G.; Guo, X.; Kang, X. Periostin: An Emerging Molecule With a Potential Role in Spinal Degenerative Diseases. Front. Med. (Lausanne) 2021, 8, 694800. [Google Scholar] [CrossRef]
- Blauvelt, A.; Chiricozzi, A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin. Rev. Allergy Immunol. 2018, 55, 379–390. [Google Scholar] [CrossRef] [Green Version]
- Xu, X.; Chang, W.; Yuan, J.; Han, X.; Tan, X.; Ding, Y.; Luo, Y.; Cai, H.; Liu, Y.; Gao, X.; et al. Periostin expression in intra-tumoral stromal cells is prognostic and predictive for colorectal carcinoma via creating a cancer-supportive niche. Oncotarget 2016, 7, 798–813. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schürch, C.M.; Bhate, S.S.; Barlow, G.L.; Phillips, D.J.; Noti, L.; Zlobec, I.; Chu, P.; Black, S.; Demeter, J.; McIlwain, D.R.; et al. Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. Cell 2020, 183, 838. [Google Scholar] [CrossRef]
Female | Male | ||
---|---|---|---|
19 | 28 | 47 (100%) | |
Age | 63.13 ± 10.95 | 61.90 ± 9.14 | 62.43 ± 9.83 |
T parameter | |||
T1 | 0 (0%) | 0 (0%) | 0 (0%) |
T2 | 7 (36.84%) | 5 (17.86%) | 12 (25.53%) |
T3 | 9 (47.37%) | 14 (50.00%) | 23 (48.94%) |
T4 | 3 (15.79%) | 9 (32.14%) | 12 (25.53%) |
N parameter | |||
N0 | 9 (47.37%) | 12 (42.86%) | 21 (44.68%) |
N1 | 8 (42.11%) | 9 (32.14%) | 17 (36.17%) |
N2 | 2 (10.53%) | 7 (25.00%) | 9 (19.15%) |
M parameter | |||
M0 | 17 (89.47%) | 19 (40.43%) | 36 (76.60%) |
M1 | 2 (10.53%) | 9 (32.14%) | 11 (23.40%) |
TNM stage | |||
I | 6 (31.58%) | 4 (14.29%) | 10 (21.28%) |
II | 4 (21.05%) | 7 (25.00%) | 11 (23.40%) |
III | 7 (36.84%) | 8 (28.57%) | 15 (31.94%) |
IV | 2 (10.53%) | 9 (32.14%) | 11 (23.40%) |
Grading | |||
G1 | 1 (5.26%) | 0 (0%) | 1 (2.13%) |
G2 | 18 (94.74%) | 28 (100%) | 46 (97.87%) |
G3 | 0 (0%) | 0 (0%) | 0 (0%) |
Tumor | Margin | p | |||
---|---|---|---|---|---|
Mean | SD | Mean | SD | ||
Periostin | −5.75 | 0.28 | −6.07 | 0.30 | <0.0001 |
IFN-γ | −6.00 | 0.31 | −6.15 | 0.35 | 0.001 |
IL-1 β | −5.84 | 0.48 | −7.07 | 0.51 | <0.0001 |
IL-17 | −6.75 | 0.28 | −6.96 | 0.30 | <0.0001 |
TNFα | −6.90 | 0.24 | −7.01 | 0.24 | 0.005 |
VEGF-A | −0.67 | 0.46 | −1.34 | 0.37 | <0.0001 |
Pair of Variables | R | p |
---|---|---|
Tumor log periostin and tumor log IFN-γ | 0.35 | 0.032 |
Tumor log periostin and tumor log IL-1 beta | 0.40 | 0.012 |
Tumor log periostin and tumor log TNFα | 0.40 | 0.013 |
Tumor log periostin and tumor log VEGF-A | 0.36 | 0.014 |
Margin log periostin and tumor log IFN-γ | 0.35 | 0.030 |
Margin log periostin and margin log IFN-γ | 0.57 | <0.0001 |
Margin log periostin and margin log IL-1 beta | 0.64 | <0.0001 |
Margin log periostin and tumor log IL-17 | 0.39 | 0.015 |
Margin log periostin and margin log IL-17 | 0.62 | <0.0001 |
Margin log periostin and tumor log TNFα | 0.45 | 0.005 |
Margin log periostin and margin log TNFα | 0.80 | <0.0001 |
Margin log periostin and tumor log VEGF-A | 0.31 | 0.037 |
Margin log periostin and margin log VEGF-A | 0.57 | <0.0001 |
Pair of Variables | Tau–Kendall’s Correlation | |
---|---|---|
Tau | p | |
Tumor periostin and budding | 0.30 | 0.02 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kula, A.; Dawidowicz, M.; Mielcarska, S.; Kiczmer, P.; Chrabańska, M.; Rynkiewicz, M.; Świętochowska, E.; Waniczek, D. Periostin in Angiogenesis and Inflammation in CRC—A Preliminary Observational Study. Medicina 2022, 58, 96. https://doi.org/10.3390/medicina58010096
Kula A, Dawidowicz M, Mielcarska S, Kiczmer P, Chrabańska M, Rynkiewicz M, Świętochowska E, Waniczek D. Periostin in Angiogenesis and Inflammation in CRC—A Preliminary Observational Study. Medicina. 2022; 58(1):96. https://doi.org/10.3390/medicina58010096
Chicago/Turabian StyleKula, Agnieszka, Miriam Dawidowicz, Sylwia Mielcarska, Paweł Kiczmer, Magdalena Chrabańska, Magdalena Rynkiewicz, Elżbieta Świętochowska, and Dariusz Waniczek. 2022. "Periostin in Angiogenesis and Inflammation in CRC—A Preliminary Observational Study" Medicina 58, no. 1: 96. https://doi.org/10.3390/medicina58010096